



## Final Appraisal Recommendation

Advice number: 0324 – May 2024

**Opicapone (Ongentys®) 50 mg hard capsule**

**Limited submission by Bial – Portela & C<sup>a</sup>, S.A**

### Recommendation of the All Wales Medicines Strategy Group

**Opicapone (Ongentys®) is recommended as an option for use within NHS Wales as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.**

#### Additional note(s):

- This advice incorporates and replaces the existing AWMSG recommendation for opicapone (Ongentys®) (Adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations, restricted within the licensed indication for use after failure of entacapone, or in patients who cannot tolerate entacapone.) (AWTTC reference number 911, originally published March 2021).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 5285), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

All Wales Medicines Strategy Group Final Appraisal Recommendation –  
0324:  
Opicapone (Ongentys®) 50 mg hard capsule May 2024

